wugen

press releases

ST. LOUIS, DEC. 3, 2018

WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

Platform demonstrates curative treatment of T-cell cancers using fratricide-resistant UCART in preclinical models

A biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform…

ST. LOUIS, Nov. 13, 2018

WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis

A biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington University in St. Louis for intellectual property and technology related to CAR-T therapies. The agreement gives WUGEN

ST. LOUIS, Nov. 1, 2018

WUGEN Announces Presentations at American Society of Hematology Annual Meeting

Company presents first clinically viable therapy to address a cancer with no effective targeted treatment

A biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform…